Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Apr
08
Today In Oncology
Analysis Shows Nearly 7 Percent of Global Clinical Trials Are Impacted by Middle East Conflict
Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer
Ablative Radiotherapy May Improves Outcomes for Patients With Large Intrahepatic Cholangiocarcinoma
Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo